Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA vaccine against influenza D virus
- Development stage
- Preclinical
- Lead developer
- Helix Biogen Institute
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
mRNA vaccine against influenza D virus is an in-silico designed mRNA vaccine candidate developed by Helix Biogen Institute. The vaccine construct is designed using immunoinformatic methods targeting the Hemagglutinin-esterase-fusion glycoprotein (HEF), which is the sole surface glycoprotein of the Influenza D Virus (IDV). The vaccine prototype comprises nine epitopes (including helper T lymphocyte (HTL), cytotoxic T lymphocyte (CTL), and linear B-cell (LBL) epitopes), an adjuvant (Human Beta Defensin 1), a tissue plasminogen activator (tPA) signal peptide, a major histocompatibility complex class I-targeting domain (MITD), a Kozak sequence, 5' and 3' untranslated regions (UTRs), and a poly-A tail. It is intended as a veterinary vaccine to prevent and control IDV outbreaks in animals (such as cattle and swine) and mitigate potential zoonotic transmission to humans.
- Other names
- mRNA vaccine against IDVuniversal mRNA vaccine against Influenza D Virus
02
Targets
TLR3 (Toll-like receptor 3)TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on mRNA vaccine against influenza D virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA vaccine against influenza D virus.